MAIN SESSION 1 – Origin of Antiphospholipid Antibodies (aPL)

• General Review – Origin of PL
• The Role of Innate and Adaptive Immunity in aPL Production
• Microbiata and Antiphospholipid Syndrome(APS)
• Are Vaccines Responsible for the Emergence of aPL?

​Joyce Rauch
Rohan Willis
Martin Kriegel
Yehuda Shoenfeld

MAIN SESSION 2 - Mechanisms of aPL-mediated Thrombosis

• General Review - aPL-mediated Thrombosis
• The Role of Post-Translational Modification of β₂GPI in aPL-mediated Thrombosis
• Cell Signaling Pathways in aPL-mediated Thrombosis
• The Role of Coagulation Pathways in aPL-mediated Thrombosis
• The Central Role of Inflammation in aPL-mediated Thrombosis

Rohan Willis
Steve Krilis
Philip G de Groot
Hannah Cohen
Jason Knight

MAIN SESSION 3 - Mechanisms of aPL-mediated Pregnancy Morbidity

• General Review - aPL-mediated Pregnancy Morbidity
• Antiphospholipid Antibody Internalisation into the Syncytiotrophoblast
• The Role of ApoER2 in aPL-mediated Placental and Endothelial Dysfunction
• Do Obstetric and Thrombotic aPL Have Differential Effects Upon Target Cells?
• Targeting β₂-Glycoprotein-I to Prevent Obstetric APS

Jane Salmon
Larry Chamley
Chieko Mineo
Ian Giles
​Pier Luigi Meroni

MAIN SESSION 4 – Abstract Recognition Award Presentations

• A Session In Memory of Silvia Pierangeli and Aziz Gharavi

​

MAIN SESSION 5 - Definition & Epidemiology of APS

• Definition of APS
• Definition of Obstetric APS
• Antiphospholipid Antibody vs APS
• Epidemiology of APS

Stephane Zuily
Guilherme De Jesus
Robert Roubey
​​Michael D Lockshin

MAIN SESSION 6 – Pediatric APS: Newborns to Teenagers

• Developmental Hemostasis
• Thrombotic and Non-thrombotic Neurological Manifestations in Children With aPL
• Should We Treat Children with APS Differently?
• Long-term Follow-up of Children Born to Mothers with APS

Patti Massicotte
Ann Yeh
Gili Kenet
​Laura Andreoli

MAIN SESSION 7 - Catastrophic APS: Microangiopathic APS to Thrombotic Storm

• How Do I Approach Thrombotic Storm?
• How Do I Approach to Catastrophic APS?

Tom Ortel
Ricard Cervera

MAIN SESSION 8 – Clinical and Prognostic Significance of “Criteria” and Non-Criteria aPL Tests

• General Overview & “Criteria” ELISA Tests
• The Significance of IgA Anticardiolipin & Anti-β₂-Glycoprotein-I Antibodies
• Lupus Anticoagulant Assay & Other Tests Relevant to Clinical Practice
• Anti-phosphatidlyserine/prothrombin Antibodies
• Anti-Domain I Antibodies – A Specific and Predictive Marker of Thrombosis

Maria Laura Bertolaccini​
Angela Tincani
Ian Mackie
Tatsuya Atsumi
Bas de Laat

MAIN SESSION 9- Prevention & Treatment of Thrombotic APS

• General Review - Primary Thrombosis Prevention
• General Review – Secondary Thrombosis Prevention
• Importance of Cardiovascular Disease Prevention in APS
• Can We Stop Anticoagulation in APS Patients with Previous Thrombosis?
• Hydroxychloroquine in APS – Where do we stand?

Guillermo Ruiz-Irastorza
Mark Crowther
Ian Bruce
David Garcia
Maria G. Tektonidou

MAIN SESSION 10- Prevention & Treatment of Obstetric Antiphospholipid Syndrome

• Assessment of Fetal Death - The Role of aPL and Other Confounding Factors
• What is the Impact of Treatment in Obstetric APS?
• What is the Role of Hydroxychloroquine in Obstetric APS?

Robert Silver
Ware Branch
Munther Khamashta

MAIN SESSION 11- Management of Non-Criteria Manifestations in APS

• Antiphospholipid Antibody Nephropathy
• Severe Thrombocytopenia
   
• Cardiac Valve Disease
• Skin Ulcers

Maria G. Tektonidou
Michelle Ugolini &
Reyhan Diz Kucukkaya
​TBD & Mary Carmen Amigo
Michelle Ugolini & TBD

MAIN SESSION 12 - Neuropsychiatric APS

• Antiphospholipid Antibodies & Brain:
  • ​​Neuroimaging Findings
  • Non-vascular Manifestations & Treatment Options
• Antiphospholipid Antibodies & Cognitive Dysfunction:
  • Potential Mechanisms and the Effect of aPL 
    In Mouse Fetal Brain Development
  • Clinical Perspectives

Simone Appenzeller
Giovanni Sanna


Guillermina Girardi
Elizabeth Kozora

DEEP DIVE SESSION 1- Antiphospholipid Syndrome Treatment Trends Task Force Report*

• Introduction & Summary of the 2013 Task Force Report
• Is There a Role for Anti-peptide Therapy in APS?
• What is New in Anti-complement Therapy in APS?
• Is mTOR Inhibition an Option in APS?
• B cell Inhibition in APS – Where do we stand?
• Statins in APS – Where do we stand?
• Other Potential Treatment Trends in APS
• Future Directions

Maria Tektonidou
Anisur Rahman
​Danieli Andrade
Guillaume Canaud
Ricard Cervera
Maria Cuadrado
Maria Gerosa
Danieli Andrade

DEEP DIVE SESSION 2 – Direct Oral Anticoagulants and APS

• General Review of Direct Oral Anticoagulants (DOACs)
• RAPS – Rivaroxaban in APS
• RAPS – Rivaroxaban in APS Pilot Trial Update
• TRAPS - Rivaroxaban in Thrombotic APS Trial Update
• ASTRO APS - Apixaban for the Secondary Thromboembolism Prevention in APS

David Garcia
Hannah Cohen
Mark Crowther
Vittorio Pengo
Scott Woller

DEEP DIVE SESSION 3 – International & National Collaborative Research Efforts in APS

• APS ACTION 6-year Anniversary & “Hydroxychloroquine Trial”
• Challenges of International Clinical Trials – 
  Contact Research Organization Perspective
• National Heart Lung and Blood Institute (NHBLI) (NIH) Support of 
  ​International Clinical Trials & Studies
• Strategies to Recruit Patients for Rare Diseases
• Update on European Forum on aPL
• Lessons Learned from a National APS Registry

Doruk Erkan
​Niti Goel

Andrei L. Kindzelski
​
Oral Alpan
Ricard Cervera
Ljudmila Stojanovich 

DEEP DIVE SESSION 4 - Disease and Risk Measurement Criteria in APS

• Introduction & the Importance of Disease/Risk Measurement in APS                         
• Damage Index in APS
• Antiphospholipid Score: A Quantitative Index for Diagnosis of APS
  & Predictive Marker of Thrombosis
• ​GAPSS: The Global APS Score
• Can We Measure APS Disease Activity?
• Quality of life in APS

Mary-Carmen Amigo
Victoria Goycochea-Robles

Tatsuya Atsumi
Savino Sciascia
Anisur Rahman
Stephane Zuily

DEEP DIVE SESSION 5 (A Joint Session with ISTH): – Guidelines for aPL Testing

• Introduction and Overview of ISTH LA Subcommittee Activities
• Lupus Anticoagulant Testing Guidelines
• Solid Phase aPL ELISA Testing Guidelines
• Conclusions and Future Collaboration Opportunities

Bas de Laat
Philip G de Groot
Katrien Devreese
Maria Laura Bertolaccini

DEEP DIVE SESSION 6 – Catastrophic APS (CAPS) Task Force Report*

• Introduction, Task Force Report, and Future Directions
• International CAPS Registry Update I: Clinical & Laboratory Characteristics
• International CAPS Registry Update II: Management
• Pathogenesis of CAPS – What Do We Know Better?

Ricard Cervera
Ignasi Rodriguez-Pento
Gerard Espinosa
Yehuda Shoenfeld 

DEEP DIVE SESSION 7 – Pediatric APS Task Force Report*

• Introduction, Task Force Report, and Future Directions
• Neonatal APS & Beyond: A General Review
• Pediatric APS Registries: Past, Present, and Future
• Probing the North American Lupus Registries for APS Data

Barry Myones
Cassyanne Aguiar
Tadej Avcin
Arzu Soybilgic

DEEP DIVE SESSION 8 – Antiphospholipid Syndrome Classification Criteria Task Force Report*

• Sapporo APS Classification Criteria: Historical Perspective
• Strengths and Limitations of Updated Sapporo APS Classification Criteria
• 14^th International Congress Task Force Report on “Non-criteria” Manifestations
• 15^th International Congress New APS Classification Criteria Initiative
• Multi-criteria Decision Analysis & 1000Minds Software for New APS Criteria
• How Do Meta-analyses Help Us Develop New Classification Criteria?

Takao Koike
Ronald Derksen
Roger Levy
Doruk Erkan
TBD
Denis Wahl

DEEP DIVE SESSION 9 – Natural Proteins Involved in Antiphospholipid Syndrome

• Introduction & General Review
• The Structure and Post-Translational Modification of β₂-Glycoprotein-I
• Reimagining APS Through the Door of Imaging: Macro-immune Complexes in APS
• Small angled X-ray Scattering of β₂-Glycoprotein-I
• Platelet-derived Chemokine & Endothelial Cell Interaction in APS

Philip G de Groot
Steve Krilis
Jacob Rand
Bas de Lat
Panayiotis Vlachoyiannopoulos

DEEP DIVE SESSION 10- New Generation aPL Tests

• Anti-β₂-Glycoprotein-I/HLA Class II Complex Antibodies in APS
• Anti-Domain IV/V Antibodies in APS
• Anti-Factor X Antibodies in APS
• Annexin A5 Resistance Assay & Alternative Functional Assays

Hisashi Arase
Pier Luigi Meroni
Bahar Artim Esen
Jacob Rand

DEEP DIVE SESSION 11 – Interplay Between Lupus and APS

• Introduction to Overlap Diseases
• Pathophysiological/Pathogenetic Interplay Between Lupus and APS
• The Impact of aPL in Lupus
• What Did We Learn From Hopkins Lupus Cohort About aPL/APS?
• Debate – Lupus and APS are Different Diseases
• Debate – Lupus and APS are the Same Disease

Michael D. Lockshin
Pier Luigi Meroni
Murat Inanc
Michelle Petri
Munther Khamashta
Joan Merrill

DEEP DIVE SESSION 12 – Oral Communications

• Etiopathogenesis: What is New?

Peggy Crow

• Clinical Manifestations: What Do We Understand Better?

Michelle Petri

• Quality of Life I: How to Assess the Impact of Disease?

Paul Fortin

• Quality of Life II: How to Assess and Prevent CVD?

Ian Bruce

• Organ Damage: Is it Possible to Prevent Damage?

Mary-Carmen Amigo

• Treatment I: Present Options & Challenges

Michelle Petri

• Treatment II: Future Options & Challenges

Joan Merrill

• Lupus & Pregnancy: Critical Issues and Common Pitfalls

Munther Khamashta

• Antiphospholipid Antibody ELISA Tests:
  Technical Aspects and Interpretation

Maria Laura Bertolaccini

• Antiphospholipid Antibody ELISA Tests:
  Technical Aspects and Interpretation (Turkish)

• Lupus Anticoagulant:
  Technical Aspects and Interpretation

Ian Mackie

• Lupus Anticoagulant:
  Technical Aspects and Interpretation (Turkish)

Reyhan Diz Kucukkaya

• Difficult-to-treat Antiphospholipid Syndrome

• Difficult-to-treat Antiphospholipid Syndrome (Turkish)

Doruk Erkan

• Obstetric Antiphospholipid Syndrome

• Antiphospholipid Antibodies/Syndrome in Lupus

• Obstetric Antiphospholipid Syndrome (Turkish)

• Antiphospholipid Antibodies/Syndrome in Lupus (Turkish)

Murat Inanc

• Digital Media for Antiphospholipid Syndrome Education

• Cardiovascular Imaging in Antiphospholipid Syndrome

• Catastrophic Antiphospholipid Syndrome

• Catastrophic Antiphospholipid Syndrome (Turkish)

• Pediatric Antiphospholipid Syndrome

• Pediatric Antiphospholipid Syndrome (Turkish)